Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 247

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 247
---
 J Warrants exercisable for 213,188 Depositary Shares, and (y) Series K Warrants to purchase an aggregate of 213,188 Depositary Shares. The warrants are immediately exercisable at an exercise price of $25.00 per Depositary Share, subject to adjustments for certain dilutive equity issuances. The aggregate gross proceeds to the Company were approximately $5.0 million. Additionally, we issued July 2024 Placement Agent Warrants to purchase 8,525 of our Depositary Shares in connection with the offering to Ladenburg and certain designees of Ladenburg.

On October 4, 2024, we effected
a ratio change to the Depositary Shares, pursuant to which the ratio of Ordinary Shares to Depositary Shares was changed such that one
Depositary Share represented 10,000 Ordinary Shares. Our Ordinary Shares were not affected by this change and no fractional Depositary
Shares were issued.

Options

We have established the Plan
to allow us to grant options to purchase Ordinary Shares (in the form of Depositary Shares) to employees and directors of the Company or any of its subsidiaries for the purpose of attracting, rewarding and retaining such persons. The Plan was originally adopted in December 2014 and amended on April 11, 2024 to govern the grant of tax-advantaged enterprise management incentive stock options and unapproved stock options by the Company. As of June 30, 2024, there were options to purchase 274,420,765 Ordinary Shares. The options lapse after ten years from the date of the grant. As of June 30, 2024, the weighted average remaining life of the options was 9.6 years.

In connection with our acquisition
of DARA Biosciences, Inc. in December 2015, we assumed all of their outstanding options. As of June 30, 2024 there were outstanding options
to purchase 99 Ordinary Shares with a weighted average remaining life of 0.9 years.

Warrants

October 2019 and May 2020 Warrants

In
October 2019, we completed a private placement with certain institutional investors, or the October Private Placement, where we issued
warrants to certain investors, or the October Private Placement Warrants, and the placement agent, Wainwright, or the Wainwright October
Warrants. In May 2020, we completed a private placement with certain institutional investors, or the May Private Placement, where we issued
warrants to certain